5-氰基-2-甲氧基苯甲酸甲酯 | 40757-12-8

• 物质功能分类: 化学试剂 - 有机试剂 - 酯类
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 5-氰基-2-甲氧基苯甲酸甲酯
• 英文名称: methyl 5-cyano-2-methoxybenzoate
• CAS: 40757-12-8
• 化学式: C₁₀H₉NO₃
• mdl: MFCD11044990
• 分子量: 191.186
• InChiKey: PIXOBZFOAGWQGO-UHFFFAOYSA-N

物化性质

• 熔点：
  101-103 °C(Solv: ligroine (8032-32-4); ethyl acetate (141-78-6))
• 沸点：
  331.7±27.0 °C(Predicted)
• 密度：
  1.20±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  59.3
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险性防范说明：
  P264,P280,P302+P352,P305+P351+P338,P332+P313,P337+P313,P362
• 危险性描述：
  H315,H319
• 储存条件：
  室温

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Methyl 5-cyano-2-methoxybenzoate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Methyl 5-cyano-2-methoxybenzoate
CAS number: 40757-12-8

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C10H9NO3
Molecular weight: 191.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-氰基-2-甲氧基苯甲酸甲酯 在 一水合肼 作用下， 以 甲醇 为溶剂， 反应 16.0h， 以90%的产率得到5-cyano-2-methoxybenzohydrazide
  参考文献：
  名称：

  [EN] N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS
  [FR] N-CYANOPYRROLIDINES AYANT UNE ACTIVITÉ EN TANT QU'INHIBITEURS DE L'USP30

  摘要：

  本发明涉及一类具有抑制去泛素化酶USP30活性的N-氰基吡咯烷衍生物，其在包括线粒体功能障碍、癌症和纤维化等多种治疗领域中具有实用性：式（I）。

  公开号：

  WO2022084479A1
• 作为产物：
  描述：

  2-甲氧基-5-甲基苯甲酸甲酯 在 sodium azide 、 copper(ll) sulfate pentahydrate 、 碘苯二乙酸 作用下， 以 乙腈 为溶剂， 以31%的产率得到5-氰基-2-甲氧基苯甲酸甲酯
  参考文献：
  名称：

  室温下将甲基芳烃直接转化为芳基腈

  摘要：

  在温和和中性条件下，甲基芳烃直接转化为芳基腈时，三个CH键被裂解（参见方案）。这种新的合成工具不仅可用于构建合成和医学上重要的芳基腈，而且还可以在温和的条件下实现CH官能化。PIDA ＝苯基乙酸二乙酸铵。

  DOI：

  10.1002/anie.200903838

文献信息

• Carboxysubstituted cyclic carboxamide derivatives
  申请人：Hoechst Marion Roussel, Inc.

  公开号：US05977139A1

  公开（公告）日：1999-11-02

  The present invention relates to novel carboxy substituted cyclic carboxamide derivatives of formula (1), ##STR1## and stereoisomers and pharmaceutically acceptable salts thereof and their use as tachykinin receptor antagonists. Such antagonists are useful in the treatment of tachykinin-mediated diseases and conditions disclosed herein including: asthma, coughs and bronchitis.

  本发明涉及新型的带有羧基取代的环戊酰胺衍生物，化学式为(1)，##STR1##及其立体异构体和药学上可接受的盐，以及它们作为速激肽受体拮抗剂的用途。这类拮抗剂在治疗包括哮喘、咳嗽和支气管炎在内的速激肽介导的疾病和症状中很有用。
• Direct C–H Cyanation of Arenes via Organic Photoredox Catalysis
  作者：Joshua B. McManus、David A. Nicewicz

  DOI：10.1021/jacs.6b12708

  日期：2017.3.1

  direct C-H functionalization of aromatic compounds are in demand for a variety of applications, including the synthesis of agrochemicals, pharmaceuticals, and materials. Herein, we disclose the construction of aromatic nitriles via direct C-H functionalization using an acridinium photoredox catalyst and trimethylsilyl cyanide under an aerobic atmosphere. The reaction proceeds at room temperature under

  多种应用都需要芳香族化合物直接 CH 官能化的方法，包括农用化学品、药物和材料的合成。在此，我们公开了在有氧气氛下使用吖啶鎓光氧化还原催化剂和三甲基氰硅烷通过直接CH官能化来构建芳香腈。该反应在室温和温和条件下进行，并已证明与多种给电子和吸电子基团、卤素、含氮和氧杂环以及含芳香族药剂相容。
• [EN] NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF<br/>[FR] NOUVEAUX COMPOSÉS EN TANT QUE LIGANDS DE RÉCEPTEUR DE CANNABINOÏDE ET LEURS UTILISATIONS
  申请人：ABBOTT LAB

  公开号：WO2009067613A1

  公开（公告）日：2009-05-28

  The present invention relates to compounds of formula (I), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, formula (I). wherein R1, R2, R3, R4, and L1 are defined in the specfication, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions. The present invention also relates to compounds of formula (II), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, formula (II). wherein R1a, R2a, Rx, and n are as defined in the specification, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

  本发明涉及式(I)的化合物，或药用盐、前药、前药的盐或其组合物，式(I)。其中R1、R2、R3、R4和L1在规范中定义，包括含有这种化合物的组合物，以及使用这种化合物和组合物治疗疾病和疾病的方法。本发明还涉及式(II)的化合物，或药用盐、前药、前药的盐或其组合物，式(II)。其中R1a、R2a、Rx和n如规范中定义，包括含有这种化合物的组合物，以及使用这种化合物和组合物治疗疾病和疾病的方法。
• BRIDGED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20190127358A1

  公开（公告）日：2019-05-02

  The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds modulate the activity of farnesoid X receptor (FXR), for example, as agonists. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

  本发明提供了式（I）的化合物： 或其立体异构体、互变异构体或药学上可接受的盐或溶剂，其中所有变量如本文所定义。这些化合物调节法尼索尔X受体（FXR）的活性，例如作为激动剂。本发明还涉及包括这些化合物的药物组合物以及利用这些化合物和药物组合物治疗与FXR失调相关的疾病、紊乱或病况的方法，例如病理性纤维化、移植排斥、癌症、骨质疏松症和炎症性疾病。
• NK-1 AND SEROTONIN TRANSPORTER INHIBITORS
  申请人：Degnan P. Andrew

  公开号：US20070249607A1

  公开（公告）日：2007-10-25

  The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating disorders associated with an excess or imbalance of tachykinins or serotonin or both.

  这项发明涵盖了公式I的化合物，包括药用盐，它们的药物组合物，以及它们在治疗与过多或不平衡的速激肽或血清素或两者都有关的疾病中的用途。